Usefulness of Calprotectin for Colon Adenoma Screening

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2012 by Konkuk University Medical Center
Sponsor:
Information provided by (Responsible Party):
Chul Min Park, MD, Konkuk University Medical Center
ClinicalTrials.gov Identifier:
NCT01719198
First received: October 30, 2012
Last updated: November 12, 2012
Last verified: November 2012
  Purpose

The fecal calprotectin assay is used widely for inflammatory bowel disease diagnosis and the assessment of the disease activity. Some adenoma patients have elevated fecal calprotectin level, which could mean the role of fecal calprotectin as a screening marker for colon adenoma. We will investigate the usefulness of fecal calprotectin as colon adenoma marker for screening in this study.


Condition
Colon Adenoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Usefulness of Fecal Calprotectin for Screening Colon Adenoma in Korean Population

Resource links provided by NLM:


Further study details as provided by Konkuk University Medical Center:

Primary Outcome Measures:
  • fecal calprotectin level [ Time Frame: 1 day (at the hospital visit) ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

stool specimen


Estimated Enrollment: 500
Study Start Date: October 2012
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients who visit KUH healthcare center for colonoscopy in Korea over 18 years old adult population

Criteria

Inclusion Criteria:

  • over 18 years old adult population

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01719198

Locations
Korea, Republic of
Konkuk University Medical Center Recruiting
Seoul, Korea, Republic of, 147-729
Contact: Chul Min Park, MD       i004@snu.ac.kr   
Sub-Investigator: Chul Min Park, MD         
Sponsors and Collaborators
Konkuk University Medical Center
Investigators
Principal Investigator: Yeo-Min Yun, MD, PhD Konkuk University
  More Information

No publications provided

Responsible Party: Chul Min Park, MD, clinical instructor, Konkuk University Medical Center
ClinicalTrials.gov Identifier: NCT01719198     History of Changes
Other Study ID Numbers: KUH1220
Study First Received: October 30, 2012
Last Updated: November 12, 2012
Health Authority: Korea: Institutional Review Board

Keywords provided by Konkuk University Medical Center:
adenoma
calprotectin

Additional relevant MeSH terms:
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on August 21, 2014